Study #2023-0467
Phase I/II study of PEGylated arginine deiminase (ADI-PEG20) with Carboplatin and Cabazitaxel in men with aggressive variant prostate cancers (AVPC)
MD Anderson Study Status
Not Accepting
Treatment Agent
ADI-PEG 20, Cabazitaxel, Carboplatin
Description
To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Prostate Cancer
Study phase:
Physician name:
Ana Aparicio
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-855-946-3759
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.